Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy side effects within the first few hours of their initial injection, with nausea and digestive symptoms typically peaking in the day or two that follow. Clinical trial data show these effects are most prominent at the start of treatment and after each dose increase, then generally settle within one to two weeks. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest picture of Wegovy's side-effect timeline comes from the STEP 1 trial, published in the New England Journal of Medicine, which followed 1,961 adults over 68 weeks. Nausea was the single most frequently reported adverse event, affecting around 44% of participants on semaglutide versus roughly 16% on placebo. Crucially, the trial found that most gastrointestinal events clustered around dose escalation periods rather than appearing at a consistent baseline throughout treatment.
In practical terms, that means the pattern most people experience is a step-up in symptoms when the dose increases, followed by a settling-down over roughly one to two weeks as the body adjusts. The NHS semaglutide medicines page describes nausea, vomiting, diarrhoea, constipation, stomach pain and burping as the most commonly reported effects, noting they tend to be worse at the start of treatment or after a dose increase.
A useful checking habit: after each new injection, jot a quick note on your phone, day, symptom, severity, roughly how long it lasted. Over two or three doses, a pattern usually becomes clear, and that record is far more useful to your prescriber than a general impression. If symptoms feel different from what you noted before, that is worth flagging.
For more on exactly when side effects begin after a Wegovy injection, we have covered the hour-by-hour picture in a dedicated piece.
Not everyone experiences meaningful side effects. In the STEP 1 data, a notable proportion of participants on semaglutide reported no gastrointestinal events at all, and those who did found them generally mild to moderate in severity. The slow titration schedule (starting at 0.25mg and increasing roughly every four weeks) exists precisely to reduce the intensity of early symptoms. The body's response to slowed gastric emptying does adapt.
Most people who do feel nausea describe it easing meaningfully within five to fourteen days of a new dose. Vomiting is less common and similarly tends to be short-lived. Constipation can persist longer at higher doses and sometimes needs active management through hydration and dietary fibre rather than waiting it out.
How quickly you personally notice symptoms depends on individual factors including your existing gut sensitivity, what you eat around the injection, and how well-hydrated you are. If nausea is making eating difficult, our practical guide to managing nausea on Wegovy covers the approaches our prescribers most often recommend. The mechanism behind semaglutide-related nausea is also explained in detail if you want the fuller picture.
The vast majority of Wegovy side effects are self-limiting and manageable. A few are not. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines flagged acute pancreatitis as a serious but infrequent risk: severe, persistent stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention rather than a wait-and-see approach. Do not assume it is ordinary nausea if the pain is intense and does not pass.
Other signs that need prompt attention include symptoms of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing), signs of significant dehydration from prolonged vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), and gallbladder-related pain (severe upper-right abdominal pain, especially after eating fatty food). The NHS semaglutide page sets out the full list of symptoms that warrant calling 999 or 111.
If you are uncertain whether a symptom is serious, err on the side of contacting a clinician. Our aftercare team is available seven days a week for patients treating with us. For anything that might be an emergency, call 999 or go to A&E. Side effects you think may be linked to treatment can be reported to the MHRA through the Yellow Card scheme, that data shapes future safety guidance for everyone.
One thing that catches people off guard is that symptoms they thought they had seen the last of can return briefly at each new dose level. That is not a sign that treatment is failing or that the body has become more sensitive. It reflects the same adjustment process repeating at a higher dose. For most people, each recurrence is shorter and milder than the first. By the time maintenance dose is reached, many patients report that the early gastrointestinal phase feels like a distant memory.
For a fuller account of how long Wegovy side effects tend to last overall, including what changes across the dose schedule, we have covered that in a separate piece. The full Wegovy side effects overview includes information on less common effects alongside the frequently reported ones. If you are weighing up your options or want to understand the broader treatment landscape before deciding, our treatment overview is a good starting point.
Our prescribers discuss side-effect timing, management and what to watch for as part of every consultation. If you would like to talk through suitability, start your free consultation and a GPhC-registered prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.